Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial) | Zendy

Oliver A. Cornely | Zendy; Johan Maertens | Zendy; Mark Bresnik | Zendy; Ramin Ebrahimi | Zendy; Andrew J. Ullmann | Zendy; Emilio Bouza | Zendy; Claus Peter Heußel | Zendy; O. Lortholary | Zendy; C. Rieger | Zendy; Angelika Boehme | Zendy; M. Aoun | Zendy; Heinz A. Horst | Zendy; Anne Thiébaut | Zendy; Markus Ruhnke | Zendy; Dietmar Reichert | Zendy; Nicola Vianelli | Zendy; Stefan W. Krause | Zendy; Eduardo Olavarría | Zendy; Raoul Herbrecht | Zendy

Open Access

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Author(s) -

Oliver A. Cornely,

Johan Maertens,

Mark Bresnik,

Ramin Ebrahimi,

Andrew J. Ullmann,

Emilio Bouza,

Claus Peter Heußel,

O. Lortholary,

C. Rieger,

Angelika Boehme,

M. Aoun,

Heinz A. Horst,

Anne Thiébaut,

Markus Ruhnke,

Dietmar Reichert,

Nicola Vianelli,

Stefan W. Krause,

Eduardo Olavarría,

Raoul Herbrecht

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/514341

Subject(s) - medicine , amphotericin b , aspergillosis , randomized controlled trial , confidence interval , regimen , voriconazole , nephrotoxicity , gastroenterology , dosing , surgery , toxicity , immunology , antifungal , dermatology

Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival benefits over amphotericin B deoxycholate, but its utility is limited by drug interactions. Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research